Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 1 to 25 of 463 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Catalog#SizeProduct NamePrice
79058 100 μg B7-1 (CD80) (Mouse), Fc fusion (Human), Avi-Tag
$310
33297 100 ml 3x CLTA4 Assay Buffer
$200
74000 10 ml 5X CD73 Assay Buffer
$190
60540 2 vials ADCC Bioassay Effector Cell F variant (Low Affinity) - Jurkat Recombinant Cell Line
$5,250
60541 2 vials ADCC Bioassay Effector Cell V variant (High Affinity) - Jurkat Recombinant Cell Line
$5,250
71273 2 vials ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat
$5,250
79381 2 vials Adenosine A2A Receptor Functional Recombinant Cell Line
$8,500
79496 1 ml AMP (500 µM)
$95
79097

Starting at:

50 µg

Anti-CD137 Agonist Antibody
Starting at:
$325
71209 100 µg Anti-CD20 Agonist Antibody
$315
71274-2 100 µg Anti-CD3 Agonist Antibody
$495
71274-1 50 µg Anti-CD3 Agonist Antibody
$345
79065-2 100 µg Anti-CD47 Antagonist Antibody
$475
79065-1 50 µg Anti-CD47 Antagonist Antibody
$335
79105-1 50 μg Anti-CD47 Antibody, PE-Labeled
$365
79105-2 100 μg Anti-CD47 Antibody, PE-Labeled
$495
79421-1 50 μg Anti-CD73 Antagonist Antibody
$335
79421-2 100 μg Anti-CD73 Antagonist Antibody
$475
71212 100 µg Anti-CTLA4 Neutralizing Antibody
$475
71295-1 50 μg Anti-GITR Antibody, PE-labeled
$345
71295-2 100 μg Anti-GITR Antibody, PE-labeled
$495
91015 100 μg Anti-IL-17A Neutralizing Antibody
$475
71226-2 100 μg Anti-LAG3 Antibody, PE-Labeled
$495
71226-1 50 μg Anti-LAG3 Antibody, PE-Labeled
$345
71219 100 µg Anti-LAG3, Neutralizing Antibody
$475

Items 1 to 25 of 463 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5